Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

31
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

31
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
31
Obesity01:24

Obesity

607
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
607
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

53
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
53
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

1.1K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
1.1K
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

35
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
35

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perspective on Epicardial Adipose tissue.

European journal of internal medicine·2025
Same author

Ruptured Sinus of Valsalva Aneurysm: Silent and Rare Cause of Heart Failure in Young Adults.

JACC. Case reports·2025
Same author

Letter in response to the article entitled "Estimation of the proportion of cardiovascular disease cases in France attributable to high concentrations of low-density lipoprotein cholesterol" by A. Gabet et al.

Archives of cardiovascular diseases·2025
Same author

Therapeutic appraisal in protracted heart failure.

The American journal of the medical sciences·2025
Same author

Outcomes of Multiorgan Heart Transplant Between Donation After Circulatory Death and Brain Death.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2024
Same author

Menopause, epicardial adiposity and preserved ejection fraction heart failure.

International journal of cardiology·2024

Related Experiment Video

Updated: Sep 5, 2025

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.3K

Cardiovascular Disease Risk Reduction and Body Mass Index.

Rohan Samson1, Pierre Vladimir Ennezat2, Thierry H Le Jemtel3

  • 1Section of Cardiology, John W. Deming Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA, 70112, USA.

Current Hypertension Reports
|July 5, 2022
PubMed
Summary
This summary is machine-generated.

Obesity increases cardiovascular disease risk through multiple pathways. Effective risk reduction in obese patients requires targeting both obesity and its associated conditions, not just hypertension and dyslipidemia.

Keywords:
Body mass indexCardiovascular diseaseHypertensionObesity

More Related Videos

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.0K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

Related Experiment Videos

Last Updated: Sep 5, 2025

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.3K
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.0K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

Area of Science:

  • Cardiovascular disease research
  • Obesity pathobiology
  • Metabolic syndrome

Background:

  • Obesity (BMI > 30 kg/m²) significantly elevates cardiovascular disease (CVD) risk.
  • Standard anti-hypertensive and lipid-lowering therapies only partially mitigate CVD risk in obese individuals.
  • Understanding obesity's complex role in CVD is crucial for effective prevention and treatment.

Purpose of the Study:

  • To review emerging aspects of obesity pathobiology.
  • To explain the limited effectiveness of current therapies in obese patients.
  • To highlight the need for comprehensive risk management strategies.

Main Methods:

  • Literature review of recent studies on obesity and cardiovascular disease.
  • Analysis of the mechanisms linking obesity to increased CVD risk.
  • Synthesis of findings on the effectiveness of current therapeutic approaches.

Main Results:

  • Obesity contributes to CVD risk via insulin resistance, endothelial dysfunction, and overactive sympathetic and renin-angiotensin-aldosterone systems.
  • These factors promote type 2 diabetes, coronary atherosclerosis, and chronic kidney disease.
  • Obesity-associated glomerulopathy further exacerbates kidney disease and CVD risk.

Conclusions:

  • Obesity presents multifaceted cardiovascular risks beyond hypertension and dyslipidemia.
  • Therapies targeting obesity and its co-morbidities are essential for optimal CVD risk reduction.
  • A holistic approach is necessary to manage cardiovascular health in obese patients.